{"id":"NCT00933686","sponsor":"Merck KGaA, Darmstadt, Germany","briefTitle":"Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome","officialTitle":"Growth Hormone Treatment of Severe Fibromyalgia Syndrome Associated With Functional Failure of Somatotropic Axis. A Multicentre, Randomized, Double-blind, Placebo-controlled Study.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2009-07-07","resultsPosted":"2013-08-02","lastUpdate":"2013-08-02"},"enrollment":113,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia"],"interventions":[{"type":"DRUG","name":"Saizen®","otherNames":["Somatropin"]},{"type":"DRUG","name":"Placebo and Saizen®","otherNames":[]}],"arms":[{"label":"Saizen®","type":"ACTIVE_COMPARATOR"},{"label":"Placebo + Saizen®","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of recombinant human growth hormone (r-hGH) treatment in severe fibromyalgia subjects with growth axis dysfunction.","primaryOutcome":{"measure":"Percentage of Participants With Less Than 11 Tender Points at Month 6","timeFrame":"Month 6","effectByArm":[{"arm":"Saizen®","deltaMin":20,"sd":null},{"arm":"Placebo + Saizen®","deltaMin":22,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":12},"locations":{"siteCount":1,"countries":["Spain"]},"refs":{"pmids":["22465047","20631018"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":55},"commonTop":["Headache","Oedema","Paraesthesia","Fibromyalgia","Carpal tunnel syndrome"]}}